Drug Price Trends for FT ALLERGY D-12HR

Average Pharmacy Cost for FT ALLERGY D-12HR

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
FT ALLERGY D-12HR 5-120 MG TAB	70677-1024-01	0.81354	EACH	2025-05-21
FT ALLERGY D-12HR 5-120 MG TAB	70677-1024-01	0.80642	EACH	2025-04-23
FT ALLERGY D-12HR 5-120 MG TAB	70677-1024-01	0.80029	EACH	2025-03-19
FT ALLERGY D-12HR 5-120 MG TAB	70677-1024-01	0.78654	EACH	2025-02-19
FT ALLERGY D-12HR 5-120 MG TAB	70677-1024-01	0.77870	EACH	2025-01-22
FT ALLERGY D-12HR 5-120 MG TAB	70677-1024-01	0.78027	EACH	2024-12-18

Market Analysis and Price Projections for Allegra-D 12HR

Introduction to Allegra-D 12HR

Allegra-D 12HR is a widely used over-the-counter (OTC) medication designed to provide relief from seasonal allergy symptoms and nasal congestion. The medication combines fexofenadine HCl, an antihistamine, with pseudoephedrine HCl, a decongestant. This combination is effective in alleviating symptoms such as sneezing, runny nose, itchy throat, and nasal congestion[2].

Market Size and Growth

The market for seasonal allergic rhinitis, which includes medications like Allegra-D 12HR, is substantial and growing. As of 2023, the seasonal allergic rhinitis market size was valued at approximately $10.5 billion. It is projected to reach $14.1 billion by 2034, with a compound annual growth rate (CAGR) of 2.76% during the period from 2024 to 2034. This growth is driven by advancements in targeted therapies, biologics, and a increasing consumer trend towards holistic health methods[3].

Sales and Revenue

Allegra-D 12HR and its generic equivalents have significant sales in the U.S. market. For instance, the brand and generic versions of Allegra-D 12HR had U.S. sales of approximately $44 million for the twelve months ending in May 2019. This figure indicates a strong market presence and consumer demand for this medication[1].

Competitive Landscape

The allergy relief market is highly competitive, with several brands and generic options available. Allegra-D 12HR competes with other popular allergy medications such as Claritin-D and Zyrtec-D. The competitive landscape is further complicated by the presence of store-brand equivalents, such as those offered by Dr. Reddy’s Laboratories, which provide affordable alternatives to consumers[1][5].

Pricing Dynamics

The pricing of Allegra-D 12HR and its generic equivalents can vary based on several factors, including the retailer, location, and availability of discounts or promotions. Generally, brand-name Allegra-D 12HR tends to be more expensive than its generic counterparts. For example, a 20-count pack of Allegra-D 12HR can range from $20 to $30, while generic versions may be priced lower, often between $10 to $20 for a similar quantity[1][5].

Price Projections

Given the projected growth of the seasonal allergic rhinitis market, it is likely that the demand for Allegra-D 12HR and similar medications will remain strong. Here are some key points to consider for price projections:

• Market Growth: The increasing market size and growing demand for allergy relief medications suggest that prices may stabilize or slightly increase due to higher demand.
• Generic Competition: The availability of generic equivalents can put downward pressure on prices, making the medication more affordable for consumers.
• Retail Dynamics: Retailers may adjust prices based on consumer demand, competition, and their own pricing strategies.

Consumer Trends and Preferences

Consumers are increasingly looking for non-drowsy, effective, and affordable allergy relief options. Allegra-D 12HR, being a non-drowsy medication, aligns well with these preferences. Additionally, the trend towards holistic health methods and natural therapies may influence some consumers to opt for alternative treatments, but the convenience and efficacy of medications like Allegra-D 12HR are likely to maintain their market share[3].

Regulatory Environment

The regulatory environment plays a crucial role in the pricing and availability of medications. Allegra-D 12HR and its generic equivalents must comply with U.S. Food and Drug Administration (USFDA) regulations. Any changes in regulatory policies or approval processes could impact the market dynamics and pricing of these medications[1].

Side Effects and Safety Considerations

While Allegra-D 12HR is generally well-tolerated, it comes with certain side effects and safety considerations. Common side effects include headache, insomnia, and nausea. The decongestant component, pseudoephedrine, can also cause nervousness, restlessness, and dizziness. These factors can influence consumer choice and may affect pricing if consumers prefer medications with fewer side effects[2].

Conclusion

The market for Allegra-D 12HR is robust, driven by the growing demand for effective allergy relief medications. While the competitive landscape and availability of generic equivalents can impact pricing, the overall trend suggests stable to slightly increasing prices due to market growth.

Key Takeaways

• Market Growth: The seasonal allergic rhinitis market is expected to reach $14.1 billion by 2034.
• Sales and Revenue: Allegra-D 12HR and its generics have significant sales, with $44 million in U.S. sales for the twelve months ending in May 2019.
• Pricing Dynamics: Prices vary based on brand, generic options, and retailer, with generics generally being more affordable.
• Consumer Trends: Consumers prefer non-drowsy, effective, and affordable options.
• Regulatory Environment: Compliance with USFDA regulations is crucial.

FAQs

Q1: What are the active ingredients in Allegra-D 12HR?

• The active ingredients in Allegra-D 12HR are fexofenadine HCl (an antihistamine) and pseudoephedrine HCl (a decongestant)[2].

Q2: How does Allegra-D 12HR compare to other allergy medications?

• Allegra-D 12HR competes with other medications like Claritin-D and Zyrtec-D, offering similar relief from allergy symptoms and nasal congestion[2][5].

Q3: What are the common side effects of Allegra-D 12HR?

• Common side effects include headache, insomnia, nausea, and side effects related to the decongestant component such as nervousness and dizziness[2].

Q4: Are there generic equivalents available for Allegra-D 12HR?

• Yes, generic equivalents are available, such as those offered by Dr. Reddy’s Laboratories, which provide affordable alternatives to consumers[1].

Q5: How is the market for seasonal allergic rhinitis expected to grow?

• The market is expected to grow from $10.5 billion in 2023 to $14.1 billion by 2034, with a CAGR of 2.76% during the period from 2024 to 2034[3].

Sources

1. Dr. Reddy's Laboratories Ltd. - "Dr. Reddy's announces the launch of over-the-counter, store-brand equivalent of Allegra-D® 12 HR Allergy and Congestion Extended-Release Tablets in the U.S. market"[1].
2. Sanofi-aventis - "ALLEGRA-D® 24 HOUR (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) Extended-Release Tablets"[2].
3. Biospace - "Seasonal Allergic Rhinitis Market to Reach US$ 14.1 Billion by 2034"[3].
4. PubMed - "Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combination tablets in the treatment of seasonal allergic rhinitis"[4].
5. CVS Health - "Allegra-D 12HR Allergy Relief & Decongestant Extended Release Tablets, Non-Drowsy"[5].

Last updated: 2025-01-02